BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y, Zhou S, Wang X, Xu J, Tao R. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther 2017;10:2595-600. [PMID: 28553124 DOI: 10.2147/OTT.S134684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Ma J, Lin Z, Ding T, Li Q, Zhang M, Kang H, Johnston PB, Ma Y, Chen B. Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study. Front Oncol 2022;12:938421. [DOI: 10.3389/fonc.2022.938421] [Reference Citation Analysis]
2 Löw S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord 2018;11:1756286418793562. [PMID: 30305848 DOI: 10.1177/1756286418793562] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
3 Xiao J, Wang S, Xu B, Yu L, Han Y, Bhagyaveni M. Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study. Journal of Healthcare Engineering 2022;2022:1-5. [DOI: 10.1155/2022/8963547] [Reference Citation Analysis]
4 Li X, Song H, Kong F, Guo Y, Chen Y, Zhang L, Gao D, Zhao X, Zhang H. Pemetrexed exerts anticancer effects by inducing G0/G1-phase cell cycle arrest and activating the NOXA/Mcl-1 axis in human esophageal squamous cell carcinoma cells. Oncol Lett 2019;17:1851-8. [PMID: 30675247 DOI: 10.3892/ol.2018.9753] [Reference Citation Analysis]
5 Morales-Martinez A, Lozano-Sanchez F, Duran-Peña A, Hoang-Xuan K, Houillier C. Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers (Basel) 2021;13:3479. [PMID: 34298693 DOI: 10.3390/cancers13143479] [Reference Citation Analysis]
6 Pan Z, Yang G, Cui J, Li W, Li Y, Gao P, Jiang T, Sun Y, Dong L, Song Y, Zhao G. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer. Front Oncol 2019;9:838. [PMID: 31544065 DOI: 10.3389/fonc.2019.00838] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fortin Ensign SP, Gathers D, Wiedmeier JE, Mrugala MM. Central Nervous System Lymphoma: Novel Therapies. Curr Treat Options Oncol 2022. [PMID: 35182298 DOI: 10.1007/s11864-021-00921-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Holdhoff M, Wagner-Johnston N, Roschewski M. Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. Onco Targets Ther 2020;13:8323-35. [PMID: 32903865 DOI: 10.2147/OTT.S192379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]